Phase 4 Bipolar Disorder Trial, Recruiting NCT05648591 Sponsor: Vanda Pharmaceuticals Condition: Bipolar Disorder
Back to Bipolar Disorder

Phase 4 Bipolar Disorder Trial, Recruiting

NCT05648591
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The patient is willing to take part and able to complete all parts of the study
  • A parent or legal guardian is willing and able to give consent on the patient's behalf
  • The patient is between 12 and 17 years old (inclusive)
  • The patient has been clinically diagnosed with either schizophrenia or bipolar I disorder

Who may not be able to join:

  • The patient has taken part in another clinical trial using an experimental drug within the last 30 days (or within 5 half-lives of that drug, whichever period is longer) before enrolling
  • The patient tests positive for drugs of abuse

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 202-734-3400

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Vanda Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
24 May 2023
Est. completion
31 March 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with treatment-emergent adverse events (TEAEs) in the treatment period.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov